Published in Medical Letter on the CDC and FDA, May 25th, 2003
The study found that the vaccine is effective in preventing bloodstream infection with the pneumococcal bacterium, an infectious agent that can also infect the lungs, causing pneumonia. Although this bloodstream infection is relatively uncommon, it is the most serious form of pneumococcal infection and is fatal in about 20% of cases. The pneumococcal polysaccharide vaccine is still recommended for seniors in order to prevent this bloodstream infection.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.